Korean Medicine (KM) Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Republic of Korea.
KM Data Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
Nutrients. 2023 May 18;15(10):2364. doi: 10.3390/nu15102364.
In cell-based regenerative medicine, induced pluripotent stem cells (iPSCs) generated from reprogrammed adult somatic cells have emerged as a useful cell source due to the lack of ethical concerns and the low risk of immune rejection. To address the risk of teratoma formation, which is a safety issue in iPSC-based cell therapy, it is essential to selectively remove undifferentiated iPSCs remaining in the iPSC-derived differentiated cell product prior to in vivo transplantation. In this study, we explored whether an ethanol extract of coptidis rhizoma (ECR) exhibited anti-teratoma activity and identified the active components involved in the selective elimination of undifferentiated iPSCs. Transcriptome analysis of iPSCs confirmed that cell death-related pathways were significantly altered by ECR treatment. Our results demonstrate that ECR effectively induced apoptotic cell death and DNA damage in iPSCs, and that reactive oxygen species generation, mitochondrial damage, caspase activation, and p53 activation were involved in ECR-mediated iPSC death. However, in iPSC-derived differentiated cells (iPSC-Diff), reduced cell viability and the DNA damage response were not observed after ECR treatment. We co-cultured iPSCs and iPSC-Diff and found that ECR treatment selectively removed iPSCs, whereas iPSC-Diff remained intact. Prior to in ovo implantation, ECR treatment of a mixed cell culture of iPSCs and iPSC-Diff significantly suppressed iPSC-derived teratoma formation. Among the main components of the ECR, berberine and coptisine showed selective cytotoxicity to iPSCs but not to iPSC-Diff. Together, these results indicate the usefulness of ECRs in preparing safe and effective iPSC-based therapeutic cell products with no risk of teratoma formation.
在基于细胞的再生医学中,由于不存在伦理问题和免疫排斥的风险低,由重编程的成体细胞产生的诱导多能干细胞(iPSC)已成为一种有用的细胞来源。为了解决 iPSC 基细胞治疗中存在的畸胎瘤形成风险这一安全问题,在体内移植前,必须选择性地去除 iPSC 衍生的分化细胞产物中残留的未分化 iPSC。在这项研究中,我们探讨了黄连乙醇提取物(ECR)是否具有抗畸胎瘤活性,并确定了参与选择性去除未分化 iPSC 的活性成分。iPSC 的转录组分析证实,ECR 处理显著改变了与细胞死亡相关的途径。我们的结果表明,ECR 可有效诱导 iPSC 发生凋亡性细胞死亡和 DNA 损伤,并且活性氧生成、线粒体损伤、半胱天冬酶激活和 p53 激活参与了 ECR 介导的 iPSC 死亡。然而,在 iPSC 衍生的分化细胞(iPSC-Diff)中,ECR 处理后未观察到细胞活力降低和 DNA 损伤反应。我们将 iPSC 和 iPSC-Diff 共培养,并发现 ECR 处理可选择性地去除 iPSC,而 iPSC-Diff 则保持完整。在鸡胚体内植入前,对 iPSC 和 iPSC-Diff 的混合细胞培养物进行 ECR 处理可显著抑制 iPSC 衍生的畸胎瘤形成。在 ECR 的主要成分中,小檗碱和黄连碱对 iPSC 表现出选择性细胞毒性,但对 iPSC-Diff 则没有。总之,这些结果表明 ECR 可用于制备安全有效的 iPSC 基治疗性细胞产品,而不会有畸胎瘤形成的风险。